FDA approves ISEMBYLD to treat spinal muscular atrophy
The U.S. Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) to treat spinal muscular atrophy in adults and children aged 2 years and older who are receiving a survival motor neuron 2 targeted treatment. According to Scholar Rock Inc., approval was based on the Phase 3 SAPPHIRE study i
<p>The U.S. Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) to treat spinal muscular atrophy in adults and children aged 2 years and older who are receiving a survival motor neuron 2 targeted treatment. According to Scholar Rock Inc., approval was based on the Phase 3 SAPPHIRE study i</p>